Ítem
Solo Metadatos
Prevalence of classic and non-classic antiphospholipid antibodies in multiple sclerosis
| dc.creator | Shor D.B.-A. | spa |
| dc.creator | Weiss G.A. | spa |
| dc.creator | Barzilai O. | spa |
| dc.creator | Ram M. | spa |
| dc.creator | Anaya, Juan-Manuel | spa |
| dc.creator | Shoenfeld Y. | spa |
| dc.creator | Sherer Y. | spa |
| dc.date.accessioned | 2020-05-25T23:55:44Z | |
| dc.date.available | 2020-05-25T23:55:44Z | |
| dc.date.created | 2015 | spa |
| dc.description.abstract | Background: The association between antiphospholipid antibodies (aPL) and multiple sclerosis (MS) has been suggested previously, but prior studies provided contradicting findings. Objectives: To characterize the expression profile of eight classic and non-classic aPL in patients diagnosed with MS. Methods: Using the BioPlex™ 2200 immunoassay, we measured the levels of serum immunoglobulin (Ig)M and IgG isotypes of three classic aPL and five non-classic aPL in 98 subjects with MS and 237 healthy controls. Results: Three non-classic aPL were significantly more prevalent among MS patients in comparison to the control group. These antibodies included IgM and IgG against phosphatidylserine- ?2GPI (PS-B2), IgG prothrombin complex (PT-PT) and IgM prothrombin (PT). The positive results according to Bonferroni correction are PS-B2 IgG and PT-PT IgG. The remaining aPL profiles did not differ significantly between the two groups. Conclusions: An association between certain non-classic aPL and MS has been established. The specific role of these autoantibodies in the pathogenesis of the condition remains uncertain. © 2015, Israel Medical Association. All rights reserved. | eng |
| dc.format.mimetype | application/pdf | |
| dc.identifier.issn | 15651088 | |
| dc.identifier.uri | https://repository.urosario.edu.co/handle/10336/22196 | |
| dc.language.iso | eng | spa |
| dc.publisher | Israel Medical Association | spa |
| dc.relation.citationEndPage | 562 | |
| dc.relation.citationIssue | No. 9 | |
| dc.relation.citationStartPage | 559 | |
| dc.relation.citationTitle | Israel Medical Association Journal | |
| dc.relation.citationVolume | Vol. 17 | |
| dc.relation.ispartof | Israel Medical Association Journal, ISSN:15651088, Vol.17, No.9 (2015); pp. 559-562 | spa |
| dc.relation.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943655947&partnerID=40&md5=447de3270c9e2afafa340f94a019e1fa | spa |
| dc.rights.accesRights | info:eu-repo/semantics/openAccess | |
| dc.rights.acceso | Abierto (Texto Completo) | spa |
| dc.source.instname | instname:Universidad del Rosario | spa |
| dc.source.reponame | reponame:Repositorio Institucional EdocUR | spa |
| dc.subject.keyword | Beta2 glycoprotein 1 | spa |
| dc.subject.keyword | Cardiolipin antibody | spa |
| dc.subject.keyword | antiphospholipid | eng |
| dc.subject.keyword | Immunoglobulin g | spa |
| dc.subject.keyword | Immunoglobulin m | spa |
| dc.subject.keyword | Phosphatidylethanolamine | spa |
| dc.subject.keyword | Phosphatidylserine | spa |
| dc.subject.keyword | Phospholipid antibody | spa |
| dc.subject.keyword | Prothrombin | spa |
| dc.subject.keyword | Prothrombin complex | spa |
| dc.subject.keyword | Immunoglobulin g | spa |
| dc.subject.keyword | Immunoglobulin m | spa |
| dc.subject.keyword | Phospholipid antibody | spa |
| dc.subject.keyword | Adult | spa |
| dc.subject.keyword | Antibody titer | spa |
| dc.subject.keyword | Article | spa |
| dc.subject.keyword | Controlled study | spa |
| dc.subject.keyword | Disease duration | spa |
| dc.subject.keyword | Female | spa |
| dc.subject.keyword | Flow cytometry | spa |
| dc.subject.keyword | Fluorescence analysis | spa |
| dc.subject.keyword | Human | spa |
| dc.subject.keyword | Immunoassay | spa |
| dc.subject.keyword | Major clinical study | spa |
| dc.subject.keyword | Male | spa |
| dc.subject.keyword | Middle aged | spa |
| dc.subject.keyword | Multiple sclerosis | spa |
| dc.subject.keyword | Protein expression | spa |
| dc.subject.keyword | Blood | spa |
| dc.subject.keyword | Case control study | spa |
| dc.subject.keyword | Cross-sectional study | spa |
| dc.subject.keyword | Immunology | spa |
| dc.subject.keyword | Multiple sclerosis | spa |
| dc.subject.keyword | Prevalence | spa |
| dc.subject.keyword | Adult | spa |
| dc.subject.keyword | Antibodies | eng |
| dc.subject.keyword | Case-control studies | spa |
| dc.subject.keyword | Cross-sectional studies | spa |
| dc.subject.keyword | Female | spa |
| dc.subject.keyword | Humans | spa |
| dc.subject.keyword | Immunoglobulin g | spa |
| dc.subject.keyword | Immunoglobulin m | spa |
| dc.subject.keyword | Male | spa |
| dc.subject.keyword | Middle aged | spa |
| dc.subject.keyword | Multiple sclerosis | spa |
| dc.subject.keyword | Prevalence | spa |
| dc.subject.keyword | Antiphospholipid syndrome (aps) | spa |
| dc.subject.keyword | Autoantibodies | spa |
| dc.subject.keyword | Autoimmunity | spa |
| dc.subject.keyword | Beta 2-glycoprotein 1 (?2gpi) | spa |
| dc.subject.keyword | Cardiolipin | spa |
| dc.subject.keyword | Immunoglobulin (ig) | spa |
| dc.subject.keyword | Multiple sclerosis (ms) | spa |
| dc.title | Prevalence of classic and non-classic antiphospholipid antibodies in multiple sclerosis | spa |
| dc.type | article | eng |
| dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | |
| dc.type.spa | Artículo | spa |



